INDV
NASDAQ · Pharmaceuticals
Indivior Pharmaceuticals Inc
$39.50
-0.10 (-0.25%)
Financial Highlights (FY 2026)
Revenue
1.18B
Net Income
200.53M
Gross Margin
84.1%
Profit Margin
17.0%
Rev Growth
+11.2%
D/E Ratio
5.43
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 84.1% | 84.1% | 64.4% | 64.4% |
| Operating Margin | 21.1% | 19.0% | 23.4% | 18.6% |
| Profit Margin | 17.0% | 16.1% | 17.8% | 21.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.18B | 1.06B | 1.33B | 1.20B |
| Gross Profit | 995.03M | 894.82M | 854.39M | 775.01M |
| Operating Income | 250.24M | 202.53M | 310.13M | 224.17M |
| Net Income | 200.53M | 162.30M | 235.99M | 261.45M |
| Gross Margin | 84.1% | 84.1% | 64.4% | 64.4% |
| Operating Margin | 21.1% | 19.0% | 23.4% | 18.6% |
| Profit Margin | 17.0% | 16.1% | 17.8% | 21.7% |
| Rev Growth | +11.2% | +11.2% | +22.2% | -7.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.04B | 2.04B | 497.34M | 438.37M |
| Total Equity | 375.35M | 375.35M | 1.81B | 1.56B |
| D/E Ratio | 5.43 | 5.43 | 0.27 | 0.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 250.19M | 213.74M | 342.24M | 373.82M |
| Free Cash Flow | — | — | 277.67M | 230.73M |